Arrowhead Pharmaceuticals News and Activities

Arrowhead Pharmaceuticals is one of the...

• Russell 3000;
• TOB Iconic 10,000.

Arrowhead Pharmaceuticals is a company listed under the stock ticker ARWR (US).

Acquisition, funding and merger involving Arrowhead Pharmaceuticals.

• Arrowhead Pharmaceuticals has just announced a $825 Million fundraising (posted on November 27 2024).

View the org chart displaying its 32 main executives

Most searched biographies at Arrowhead Pharmaceuticals

• Christopher Anzalone, Chief Executive Officer and Chairman of the ...
• Mauro Ferrari, Director
• Michael Perry, Director

Create your alert
to follow the executive moves at Arrowhead Pharmaceuticals.

Arrowhead Pharmaceuticals has 2,405 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).

Popular M&A news in Biotechnology

• IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).
• NewLimit has just announced a $435 Million fundraising (posted on June 3 2026).
• Rallybio and Avenzo Therapeutics have announced they will merge  (posted on June 1 2026)..

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Valerie Hanote - Non-Executive Director at Eurofins

Learn more about the Biotechnology industry

Press releases by Arrowhead Pharmaceuticals

• Arrowhead Pharmaceuticals to Participate in Upcoming December 2024 Conferences - Arrowhead Pharmaceuticals, Inc.
• Arrowhead Pharmaceuticals Reports 2024 Fiscal Year-End Results - Arrowhead Pharmaceuticals, Inc.
• Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity - Arrowhead Pharmaceuticals, Inc.
• Arrowhead Pharmaceuticals Announces Global License and Collaboration Agreement with Sarepta Therapeutics for Multiple Clinical and Preclinical Programs - Arrowhead Pharmaceuticals, Inc.
• Arrowhead Pharmaceuticals Presents New Data at AHA24 from PALISADE Phase 3 Study and Open-Label Extension from MUIR and SHASTA-2 Studies of Plozasiran - Arrowhead Pharmaceuticals, Inc.
• Arrowhead Pharmaceuticals Submits New Drug Application to U.S. FDA for Plozasiran for the Treatment of Familial Chylomicronemia Syndrome - Arrowhead Pharmaceuticals, Inc.
• Arrowhead Pharmaceuticals to Webcast 2024 Fiscal Year End Results - Arrowhead Pharmaceuticals, Inc.
• Arrowhead Pharmaceuticals to Participate in Upcoming November 2024 Conferences - Arrowhead Pharmaceuticals, Inc.
• Arrowhead Pharmaceuticals Launches New Disease Awareness Campaign, ‘We’ll Get There Soon,’ to Inspire Hope for the Rare Disease Community Affected by Familial Chylomicronemia Syndrome - Arrowhead Pharmaceuticals, Inc.
• Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Arrowhead Pharmaceuticals, Inc.
• View more press releases Close

Social media about Arrowhead Pharmaceuticals

• Arrowhead Pharmaceuticals on Wikipedia, Google News & Yahoo Finance
• Arrowhead Pharmaceuticals on LinkedIn, X (Twitter) & YouTube